Printer Friendly

Trovagene Adds Yale and Kansas U Cancer Centers to Clinical Trial Sites for Study of PCM-075 in Patients with AML.

M2 PHARMA-February 16, 2018-Trovagene Adds Yale and Kansas U Cancer Centers to Clinical Trial Sites for Study of PCM-075 in Patients with AML

(C)2018 M2 COMMUNICATIONS

- San Diego, California-based molecular diagnostics company Trovagene, Inc. (NASDAQ: TROV) has added two institutions, Yale Cancer Center and Kansas University Cancer Center to conduct its Phase 1b/2 open-label, multicenter trial of PCM-075 in patients with acute myeloid leukemia (AML), the company said.

Both centers are now actively screening and enrolling patients. The trial will be conducted at 10 sites throughout the US and is expected to enroll approximately 74 patients.

The open-label, multicenter Phase 1b/2 trial is designed to evaluate the safety of PCM-075 in combination with either low-dose cytarabine or decitabine in patients with AML, and to identify the maximum tolerated dose in Phase 1b to administer to further evaluate the safety and preliminary efficacy in Phase 2.

PCM-075, a highly-selective adenosine triphosphate competitive inhibitor of the serine/threonine polo-like-kinase 1 (PLK 1) enzyme that is over-expressed in multiple hematologic and solid tumor cancers, has demonstrated synergy in preclinical studies with over 10 chemotherapeutic and target agents used in hematologic and solid tumor cancers, including FLT3 and HDAC inhibitors, taxanes, and cytotoxins.

Trovagene is developing oncology therapeutics for improved cancer care by leveraging its proprietary precision cancer monitoring technology in tumor genomics.

The company has broad intellectual property and proprietary technology to measure circulating tumor DNA (ctDNA) in urine and blood to identify and quantify clinically actionable markers for predicting response to cancer therapies.

Kansas University Cancer Center is dedicated to the eradication of cancer, and offers patients many new options for cancer treatment and prevention.

Yale Cancer Center is one of only 49 National Cancer Institute-designated comprehensive cancer centers in the nation and the only such center in southern New England. It plays a vital role in reducing morbidity and mortality from cancer through scientific research, cancer prevention, and innovative cancer treatment.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2018 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Feb 16, 2018
Words:334
Previous Article:Zipnosis Names Dr. Lisa Ide as CMO.
Next Article:SeraCare Launches CNV-Specific Reference Material for Gene Amplifications in Breast, Lung, and Brain Cancer.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters